She said Mylan receives around $100 for a pack of two pens, with the rest covering middle-men and manufacturing costs. Following criticism of its pricing of EpiPen, Mylan has launched an identical ...

Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug. Cheaper competition to off-patent Advair has been ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Amir John Jaami, 97, Vancouver, died June 7, 2025. Camas Cremation and Burial Services, 360-858-8919. Arthur Eugene Noel, 87, Vancouver, died June 2, 2025. Hamilton ...

Rotten Tomatoes, home of the Tomatometer, is the most trusted measurement of quality for Movies & TV. The definitive site for Reviews, Trailers, Showtimes, and Tickets ...

Europe’s regulator has called for generic medicines from manufacturers including Novartis’ Sandoz unit, Teva and Mylan to be pulled from the market, after US inspectors found evidence that ...

The FDA approval of Mylan's Copaxone copy is particularly significant, as it is a 'complex generic' - a class of drugs for which the US regulator says it will aim to speed up approvals.

Theravance Biopharma (NASDAQ:TBPH) and partner Mylan reached a settlement agreement with Eugia Pharma over a patent dispute concerning the lung disease treatment, Yupelri inhalation solution. The ...

Generic drugmaker Viatris has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi's ...

Get the latest health news, diet & fitness information, medical research, health care trends and health issues that affect you and your family on ABCNews.com ...

Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain ...